|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
[p=23, null, center]Replicor to disclose clinical update on the REP 401 trial at HEP DART 2017
[p=23, null, left]MONTREAL, November 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today its accepted oral presentation at the 2017 HEP DART meeting, to be held from December 3-7, 2017 in Kona, HI, USA (http://www.virology-education.com/event/upcoming/hep-dart-2017/).[p=23, null, left]Replicor’s oral presentation will take place on December 7, 2017 during Oral Abstract Session VII and will feature updated on-treatment and follow-up clinical data from its ongoing REP 401 trial, which has already demonstrated the unique ability of REP 2139 to achieve HBsAg loss on therapy in a high rate of patients when used with TDF and pegylated interferon, resulting in a functional control of HBV infection (HBsAg < 1IU/mL, HBV DNA < LLOQ) persisting after all therapy is removed (functional remission) in 80% of patients.[p=23, null, left]About Replicor[p=23, null, left]Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com. |
|
发表于 2017-11-28 22:04
